Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Pulmonary Arterial Hypertension Clinical Trials

20 recruiting trials for Pulmonary Arterial Hypertension. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
20
Total Trials
20
Recruiting Now
1
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT05368467

National Registry and Cohort Study of Pulmonary Vascular Disease

This is a observational、multicenter, prospective cohort study for patients with pulmonary hypertension (PH). The purposes of this study were to evaluate the etiology、clinical...

Sponsor: Nanjing First Hospital, Nanjing Medical UniversityEnrolling: 100013 locations
RECRUITINGPhase 2NCT06104228

129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

The overall study objectives outlined in this study are to derive 129Xe MRI pulmonary vascular biomarker signatures that differentiate common subtypes of PAH and to determine the...

Sponsor: Bastiaan DriehuysEnrolling: 201 location
RECRUITINGPhase 3NCT04062565

Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those...

The purpose of this study is to determine if there is a greater effect to patients with advanced pulmonary arterial hypertension (PAH) by using a combination of two drugs,...

Sponsor: University of ArizonaEnrolling: 201 location
RECRUITINGNCT05665556

REgistry of Pulmonary Arterial Hypertension Associated With CONNECTIVE Tissue Diseases (RECONNECTIVE)

The RECONNECTIVE Registry is an observational single center study, focused on the subgroup of precapillary pulmonary hypertension related to connective tissue diseases. All...

Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranEnrolling: 1701 location
RECRUITINGNCT06605794

FreeFlow Percutaneous Atrial Septal Shunt for IPAH

The goal of this clinical trial is to explore the safety and efficacy of the FreeFlow percutaneous atrial septal shunt for treatment of idiopathic pulmonary arterial hypertension....

Sponsor: Shanghai Zhongshan HospitalEnrolling: 301 location
RECRUITINGNCT06549452

Mobile Health Intervention to Improve Exercise in Pediatric PH

Children and adults with pulmonary arterial hypertension (PAH) have severely reduced daily activity compared to healthy populations. In adults, investigators recently demonstrated...

Sponsor: Vanderbilt University Medical CenterEnrolling: 501 location
RECRUITINGPhase 4NCT06658522

Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the...

Pulmonary arterial hypertension (PAH) is a progressive disease characterized by vascular remodelling resulting in elevated pressures in the pulmonary artery (PA). This elevated...

Sponsor: Amsterdam UMC, location VUmcEnrolling: 201 location
RECRUITINGPhase 2NCT04991454

Xenon MRI Pulm Hypertension

The overall objective outlined in this study is to determine how pulmonary vascular remodeling in PAH at a cellular and pathological level is associated with changes in gas...

Sponsor: Bastiaan DriehuysEnrolling: 601 location
RECRUITINGPhase 1NCT06481852

A Placebo-controlled, Randomized Clinical Trial to Assess the Safety, Feasibility, and Pharmacokinetics of Microbiota...

This pilot clinical trial will evaluate the initial safety, feasibility, and pharmacokinetics of microbiota transplant therapy (MTT) with antibiotic pre-conditioning and fiber...

Sponsor: University of MinnesotaEnrolling: 241 location
RECRUITINGNCT05464095

The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study

Patients with pulmonary arterial hypertension (PAH) have reduced health related quality of life (HRQOL) and impaired exercise capacity. Despite fourteen approved therapies, most...

Sponsor: Vanderbilt University Medical CenterEnrolling: 1001 location
RECRUITINGNCT06954727

China Pulmonary Vascular Disease Intervention Diagnosis and Management Study-right Heart Catheterization

Right heart catheterization(RHC) plays a crucial role in the diagnosis and treatment of pulmonary vascular diseases(PVD). In China, the lack of equipment and technical expertise...

Sponsor: China-Japan Friendship HospitalEnrolling: 100001 location
RECRUITINGNCT05566002

Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension

Pulmonary hypertension represents a challenging and heterogeneous condition that is associated with high mortality and morbidity if left untreated. Artificial intelligence is used...

Sponsor: Chinese Pulmonary Vascular Disease Research GroupEnrolling: 20001 location
RECRUITINGNCT04808596

Pulmonary Hypertension Biorepository and Registry

Establish a pulmonary hypertension registry and biorepository to lead towards a further understanding of the disease.

Sponsor: University of Kansas Medical CenterEnrolling: 3001 location
RECRUITINGNCT06454838

Exercise Capacity Muscle Oxygenation and Arterial Stiffness in Children With Pulmonary Arterial Hypertension

The primary aim is to evaluate pulmonary function, respiratory muscle strength, upper and lower extremity exercise capacity, muscle oxygenation, dyspnea, peripheral muscle...

Sponsor: Gazi UniversityEnrolling: 261 location
RECRUITINGNCT04071327

Pulmonary Hypertension Association Registry

The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects...

Sponsor: Pulmonary Hypertension Association, Inc.Enrolling: 300020 locations
RECRUITINGPhase 2NCT01712620

Spironolactone for Pulmonary Arterial Hypertension

Background: \- High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. In spite of recent advances in treatment, the death rate...

Sponsor: National Institutes of Health Clinical Center (CC)Enrolling: 701 location
RECRUITINGNCT06405126

Validation of a Machine Learning Predictive Model to Distinguish Post-capillary Pulmonary Hypertension

In this study the diagnostic accuracy of a diagnostic tool for the diagnosis of post-capillary pulmonary hypertension will be investigated. The diagnostic tool was designed based...

Sponsor: KU LeuvenEnrolling: 1004 locations
RECRUITINGNCT04278404

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of...

The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults...

Sponsor: Duke UniversityEnrolling: 500020 locations
RECRUITINGNCT02691689

Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions

Pulmonary arterial hypertension (PAH) in patients with congenital heart disease (CHD) is associated with considerable morbidity and even mortality. Next to environmental risk...

Sponsor: Universitaire Ziekenhuizen KU LeuvenEnrolling: 211 location
RECRUITINGNCT06528418

Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath

The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) marker molecules. This model...

Sponsor: ChromX HealthEnrolling: 100001 location

Frequently Asked Questions

There are currently 20 clinical trials for Pulmonary Arterial Hypertension, with 20 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Pulmonary Arterial Hypertension, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Pulmonary Arterial Hypertension, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.